DNA methyltransferase inhibitor CDA-2 synergizes with high-dose thiotepa and paclitaxel in killing breast cancer stem cells

Frontiers in Bioscience - Elite

Volumn 3 E, Issue 1, 2011, Pages 240-249

  Lu, Zhihao ^a   Jia, Jun ^a   Di, Lijun ^a   Song, Guohong ^a   Yuan, Yanhua ^a   Ma, Bo ^a   Yu, Jing ^a   Zhu, Yulin ^a   Wang, Xiaoli ^a   Zhou, Xinna ^a   Ren, Jun ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Breast Cancer Stem Cells; Cytotoxic Drug; Hedgehog Signaling Pathway; High dose Chemotherapy

Indexed keywords

CELL DIFFERENTIATION AGENT; CYTOTOXIC AGENT; DNA METHYLTRANSFERASE INHIBITOR; DOXORUBICIN; HERMES ANTIGEN; PACLITAXEL; SMOOTHENED PROTEIN; THIOTEPA; TRANSCRIPTION FACTOR GLI1; UNCLASSIFIED DRUG; CD24 ANTIGEN; CELL DIFFERENTIATION AGENT II; DNA METHYLTRANSFERASE; PEPTIDE; PHENYLACETIC ACID DERIVATIVE; PRIMER DNA; SONIC HEDGEHOG PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER RESISTANCE; CANCER STEM CELL; CELL ASSAY; CELL ISOLATION; CELL PROLIFERATION; CELL STRAIN MCF 7; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; TARGET CELL DESTRUCTION; BREAST TUMOR; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ANTAGONISM; FEMALE; FLOW CYTOMETRY; GENETICS; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ERINACEIDAE;

ANTIGENS, CD24; ANTIGENS, CD44; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DNA MODIFICATION METHYLASES; DNA PRIMERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; FLOW CYTOMETRY; HEDGEHOG PROTEINS; HUMANS; NEOPLASTIC STEM CELLS; PACLITAXEL; PEPTIDES; PHENYLACETATES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; THIOTEPA;

EID: 79957870347     PISSN: 19450494     EISSN: 19450508     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. A Jemal, T Murray, E Ward, A Samuels, RC Tiwari, A Ghafoor, EJ Feuer, MJ Thun: Cancer statistics. CA Cancer J Clin 55, 5-26 (2003)
2. F Yu, H Yao, P Zhu, X Zhang, Q Pan, C Gong, Y Huang, X Hu, F Su, J Lieberman, E Song: Let-7 Regulates Self Renewal and Tumorigenicity of Breast Cancer Cells. Cell 131, 1109-1123 (2007) (Pubitemid 350235025)
3. SK Singh, C Hawkins, ID Clarke, JA Squire, J Bayani, T Hide, RM Henkelman, MD Cusimano, PB Dirks: Identification of human brain tumour initiating cells. Nature 432, 396-401 (2004) (Pubitemid 39551674)
4. M Al-Hajj, MS Wicha, A Benito-Hernandez, SJ Morrison, MF Clarke: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100, 3983-3988 (2003) (Pubitemid 36418143)
5. AT Collins, PA Berry, C Hyde, MJ Stower, NJ Maitland: Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65, 10946-10951 (2005) (Pubitemid 41713363)
6. D Fang, TK Nguyen, K Leishear, R Finko, AN Kulp, S Hotz, PA Van Belle, X Xu, DE Elder, M Herlyn: A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 65, 9328-9337 (2005) (Pubitemid 41508000)
7. D Ponti, A Costa, N Zaffaroni, G Pratesi, G Petrangolini, D Coradini, S Pilotti, MA Pierotti, MG Daidone: Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 65, 5506- 5511 (2005) (Pubitemid 40911148)
8. M Shipitsin, LL Campbell, P Argani, S Weremowicz, N Bloushtain-Qimron, J Yao, T Nikolskaya, T Serebryiskaya, R Beroukhim, M Hu, MK Halushka, S Sukumar, LM Parker, KS Anderson, LN Harris, JE Garber, AL Richardson, SJ Schnitt, Y Nikolsky, RS Gelman, K Polyak: Molecular definition of breast tumor heterogeneity. Cancer Cell 11, 259-273 (2007) (Pubitemid 46349843)
9. R Liu, X Wang, GY Chen, P Dalerba, A Gurney, T Hoey, G Sherlock, J Lewicki, K Shedden, MF Clarke: The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 356, 217-226 (2007) (Pubitemid 46143225)
10. JF Gong, LJ Di, J Ren: Phenotype analysis and correlations of breast cancer stem cells with drug-resistant related molecular markers. Cytotherapy 9 (suppl), 215 (2007)
11. M Kakarala, MS Wicha: Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J Clin Oncol 26, 2813-2820 (2008)
12. AH Sims, A Howell, SJ Howell, RB Clarke: Origins of breast cancer subtypes and therapeutic implications. Nat Clin Pract Oncol 4, 516-525 (2007) (Pubitemid 47351462)
13. C Massard, E Deutsch, JC Soria: Tumor stem celltargeted treatment: elimination or differentiation. Ann Oncol 17, 1620-1624 (2006) (Pubitemid 44680880)
14. A Taddei, D Roche, WA Bickmore, G Almouzni: The effects of histone deacetylase inhibitors on heterochromatin: implications for anticancer therapy? EMBO Rep 6, 520-524 (2005) (Pubitemid 40973959)
15. D Mottet, V Castronovo: Histone deacetylases: target enzymes for cancer therapy. Clin Exp Metastasis 25,183- 189 (2008)
16. CJ Yao, GM Lai, CF Chan, YY Yang, FC Liu, SE Chuang : Differentiation of pheochromocytoma PC12 cells induced by human urine extract and the involvement of the extracellular signal-regulated kinase signaling pathway. J Altern Complement Med 11, 903-908 (2005) (Pubitemid 41739362)
17. J Huang, M Yang, H Liu, J Jin: Human urine extract CDA-2 induces apoptosis of myelodysplastic syndromederived MUTZ-1 cells through the PI3K/Akt signaling pathway in a caspase-3-dependent manner. Acta Pharmacol Sin 29, 951-964 (2008)
18. CL Ming, PL Christine: Methyltransferase inhibitors as excellent differentiation helper inducers for differentiation therapy of cancer. Bulletin Chinese Cancer 11, 166-168 (2002)
19. FY Feng, Q Li, CG Ling, Y Zhang, FZ Qin, HQ Wang, WX Huang, SC Jiao, Q Chen, MZ Li, YZ Zhu, MZ Zhou, J Ren, YT Gao, JP Zhao, RS Zheng, WH Zhao, ZQ Meng, F Li, QZ Zhang, DL Zhao, LY Xu, YQ Zhang, YJ Zhang, ZJ Wang, SQ Liu and MC Liau: Phase III clinical trials of the cell differentiation agent-2 (CDA-2): Therapeutic efficacy on breast cancer, non-small cell lung cancer and primary hepatoma. Chinese J Clin Oncol 2, 706-716 (2008)
20. J Chen, QY Zhao, XZ Ma: The inhibitory effect of uroacitide against human gastric cancer cell SGC7901 in vitro. Modern Medicine & Health 1, 2-4 (2008)
21. JP Jia, XY Zhong, CL Lin: The Effect of Uroacitide on the Proliferation and Differentiation of Human Endometrial Carcinoma Cell Line EAC. Chinese J Clin Oncol 5,290- 292 (2008)
22. J Huang, MYang, H Liu, J Jin: CDA-II, a urinary preparation, induces growth arrest and apoptosis of human leukemia cells through inactivation of nuclear factorkappaB in a caspase-dependent manner. Food Chem Toxicol 47, 40-49 (2009)
23. UA Nitz, S Mohrmann, J Fischer, W Lindemann, WE Berdel, C Jackisch, C Werner, C Ziske, H Kirchner, B Metzner, R Souchon, U Ruffert, G Schütt, A Pollmanns, HJ Schmoll, C Middecke, J Baltzer, I Schrader, H Wiebringhaus, Y Ko, S Rosel, T Schwenzer, P Wernet, A Hinke, HG Bender, M Frick: Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial. Lancet 366, 1935-1944 (2005) (Pubitemid 41713983)
24. MS Tallman, R Gray, NJ Robert, CF LeMaistre, CK Osborne, WP Vaughan, WJ Gradishar, TM Pisansky, J Fetting, E Paietta, HM Lazarus: Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med 349,17-26 (2003) (Pubitemid 36765099)
25. O Gluz, UA Nitz, N Harbeck, E Ting, R Kates, A Herr, W Lindemann, C Jackisch, WE Berdel, H Kirchner, B Metzner, F Werner, G Schütt, M Frick, C Poremba, R Diallo-Danebrock, S Mohrmann: Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial. Ann Oncol 19, 861-70 (2008) (Pubitemid 351649186)
26. MC Cheang, D Voduc, C Bajdik, S Leung, S McKinney, SK Chia, CM Perou, TO Nielsen: Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14, 1368-1376 (2008) (Pubitemid 351413917)
27. G Honeth, P Bendahl, M Ringnér, L Saal, S Gruvberger-Saal, K Lovgren, D Grabau, M Ferno, A Borg, C Hegardt: The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res 10, R53 (2008)
28. S Liu, G Dontu, MS Wicha: Mammary stem cells, selfrenewal pathways, and carcinogenesis. Breast Cancer Res 7, 86-95 (2005) (Pubitemid 40704127)
29. C Sheridan, H Kishimoto, RK Fuchs, S Mehrotra, P Bhat-Nakshatri, CH Turner, R Goulet, S Badve, H Nakshatri: CD44 (+)/CD24 (-) breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res 8, R59 (2006)
30. TM Philips, WH McBride, F Pajonk: The response of CD44+/CD24-/lower breast cancer-initiating cells to radiation. J Natl Cancer Inst 98, 1777-1785 (2006) (Pubitemid 46017929)
31. B Kreike, M van Kouwenhove, H Horlings, B Weigelt, H Peterse, H Bartelink, MJ van de Vijver: Gene expression profiling and histopathological characterization of triplenegative/ basal-like breast carcinomas. Breast Cancer Res 9, R65 (2007)
32. E Charafe-Jauffret, C Ginestier, F Monville, P Finetti, J Adelaide, N Cervera, S Fekairi, L Xerri, J Jacquemier, D Birnbaum, F Bertucci: Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene 25, 2273-2284 (2006)
33. LA Gordon, KT Mulligan, H Maxwell-Jones, M Adams, PA Walker, JL Jones: Breast cell invasive potential relates to the myoepithelial phenotype. Int J Cancer 106, 8-16 (2003) (Pubitemid 36750382)
34. R Neve, K Chin, J Fridlyand, J Yeh, F Baehner, T Fevr, L Clark, N Bayani, J Coppe, F Tong: A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10, 515-527 (2006) (Pubitemid 44854747)
35. M Dean, T Fojo, S Bates: Tumour stem cells and drug resistance. Nat Rev Cancer 5, 275- 284 (2005) (Pubitemid 40488633)
36. CE Eckfeldt, EM Mendenhall, CM Verfaillie: The molecular repertoire of the 'almighty' stem cell. Nat Rev Mol Cell Biol 6, 726-737 (2005) (Pubitemid 41742796)
37. M Mimeault, R Hauke, PP Mehta, SK Batra: Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers. J Cell Mol Med 11 981-1011 (2007) (Pubitemid 350037046)
38. M Mimeault, SK Batra: Interplay of distinct growth factors during epithelial mesenchymal transition of cancer progenitor cells and molecular targeting as novel cancer therapies. Ann Oncol 18, 1605-1619 (2007) (Pubitemid 47506246)
39. CD Peacock, Q Wang, GS Gesell, IM Corcoran-Schwartz, E Jones, J Kim, WL Devereux, JT Rhodes, CA Huff, PA Beachy, DN Watkins, W Matsui: Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proc Natl Acad Sci USA 104, 4048-4053 (2007) (Pubitemid 47181576)
40. S Liu, G Dontu, ID Mantle, S Patel, N Ahn, KW Jackson, P Suri, MS Wicha: Hedgehog signaling and Bmi-1 regulate selfrenewal of normal and malignant human mammary stem cells. Cancer Res 66, 6063-6071 (2006)
41. EE Bar, A Chaudhry, A Lin, X Fan, K Schreck, W Matsui, S Piccirillo, AL Vescovi, F DiMeco, A Olivi, CG Eberhart: Cyclopaminemediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells 25, 2524-2533 (2007) (Pubitemid 47582744)
42. V Clement, P Sanchez, N de Tribolet, I Radovanovic, I Ruiz, A Altaba: Hedgehog-Gli-1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr Biol 17, 165-172 (2007) (Pubitemid 46107823)
43. X Zhang, N Harrington, RC Moraes, M F Wu, SG Hilsenbeck, MT Lewis : Cyclopamine inhibition of human breast cancer cell growth independent of Smoothened (Smo). Breast Cancer Res Treat 115, 505-521 (2009)
44. G Feldmann, N Habbe, S Dhara, S Bisht, H Alvarez, V Fendrich, R Beaty, M Mullendore, C Karikari, N Bardeesy, MM Ouellette, W Yu, A Maitra: Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer. Gut 57, 1420-1430 (2008)
45. EE Bar, D Stearns: New developments in medulloblastoma treatment: the potential of a cyclopaminelovastatin combination. Expert Opin Investig Drugs 17, 185-195 (2008) (Pubitemid 351578199)
46. ME Moynahan, TY Cui, M Jasin: Homology-directed DNA repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation. Cancer Res 61, 4842-4850 (2001) (Pubitemid 32691900)
47. JE Quinn, RD Kennedy, PB Mullan, PM Gilmore, M Carty, PG Johnston, DP Harkin: BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 63, 6221-6228 (2003) (Pubitemid 37255167)
48. N Kroger, W Achterrath, S Hegewisch-Becker, K Mross, AR Zander: Current options in treatment of anthracycline-resistant breast cancer. Cancer Treat Rev 25, 279-91 (1999) (Pubitemid 29507299)
49. A Sabharwal, MR Middleton: Exploiting the role of O6-methylguanine-DNA- methyltransferase (MGMT) in cancer therapy. Curr Opin Pharmacol 6, 355-63 (2006)
50. D Beier, S Rohrl, DR Pillai, S Schwarz, LA Kunz- Schughart, P Leukel, M Proescholdt, A Brawanski, U Bogdahn, A Trampe-Kieslich, B Giebel, J Wischhusen, G Reifenberger, P Hau, CP Beier: Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res 68, 5706-5715 (2008)